Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Pepper, Dominique J ^a,b   Marais, Suzaan ^a,c   Bhaijee, Feriyl ^b   Wilkinson, Robert J ^a,c,d,e   de Azevedo, Virginia ^f   Meintjes, Graeme ^a,c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c GF Jooste Hospital   (South Africa)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^f City Health   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; SOUTH AFRICA; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMBULATORY CARE FACILITIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS;

EID: 84862492440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037634     Document Type: Article

References (19)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 163(9): 1009 21.
2. Middelkoop K, Bekker LG, Myer L, Johnson LF, Kloos M, (2011) Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr. 56(3): 263 9.
3. Ciglenecki I, Glynn JR, Mwinga A, Ngwira B, Zumla A, (2007) Population differences in death rates in HIV-positive patients with tuberculosis. Int J Tuberc Lung Dis. 11(10): 1121 8.
4. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 362(8): 697 706.
5. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 365(16): 1492 501.
6. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 365(16): 1482 91.
7. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, (2011) CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 365(16): 1471 81.
8. Lawn SD, Wood R, (2012) Timing of antiretroviral therapy for HIV-1-associated tuberculosis. N Engl J Med. 366(5): 474.
9. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, (2009) HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis. 9: 42.
10. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, (2007) Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 11(4): 412 6.
11. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, (2010) Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 10: 83.
12. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, (2011) Barriers to initiation of antiretrovirals in HIV-infected patients receiving antituberculosis treatment. PLoS One 6(5): e20077.
13. Business Trust & dplg, (2007) Khayelitsha Nodal Economic Development Profile. Available:http://www.btrust.org.za/index.php?id=148&tx_abdownloads_pi1[action]=getviewcatalog&tx_abdownloads_pi1[category_uid}=26&tx_abdownloads_pi1[cid]=120&cHash=064d6b4433. Accessed 2012 Apr 30.
14. South African Department of Health (2004) The South African National Tuberculosis Control Programme Practical Guidelines. Available:http://www.kznhealth.gov.za/chrp/documents/Guidelines/Guidelines%20National/Tuberculosis/SA%20TB%20Guidelines%202004.pdf Accessed 2012 Apr 30.
15. ETR.NET of South Africa, (2010) The Electronic Tuberculosis Register. Available:http://www.etrnet.info/Default.aspx. Accessed 2011 Apr 30.
16. Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, (2010) Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 24(13): 2041 50.
17. MacPherson P, Moshabela M, Martinson N, Pronyk P, (2009) Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg. 103(6): 588 93.
18. Mossdorf E, Stoeckle M, Mwaigomole EG, Chiweka E, Kibatala PL, (2011) Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis. 11(1): 98.
19. Greig J, O'Brien D, Ford N, Spelman T, Sabapathy K, (2011) Reduced mortality and loss to follow-up in integrated compared with vertical programmes providing antiretroviral treatment in sub-Saharan Africa. J Acquir Immune Defic Syndr. 59(5): e92 8.